GLP-1 Cost Calculator
Compare the true cost of different GLP-1 medication options over time.
Disclaimer: Costs are approximate and may vary. Insurance copays depend on plan specifics. Compounded pricing may change.
Compare GLP-1 Costs
Compounded (Trimi)
$3,588
over 12 months ($299/mo)
Potential savings with Trimi vs brand:
$12,600 saved over 12 months
Understanding GLP-1 Costs
The cost of GLP-1 medications varies dramatically based on how you access them. Brand-name medications at retail pharmacies are the most expensive. Insurance coverage can reduce costs significantly but requires prior authorization. Compounded options through providers like Trimi offer the most affordable cash-pay option.
Frequently Asked Questions
Why is brand-name GLP-1 so expensive?
Brand-name GLP-1 medications (Wegovy, Zepbound) are priced high by manufacturers due to patent protection, high R&D costs, and strong demand. Compounded versions use the same active ingredient at a fraction of the cost, made by licensed compounding pharmacies.
Is compounded semaglutide safe?
Compounded semaglutide from reputable pharmacies uses pharmaceutical-grade ingredients and follows FDA guidelines for compounding. Trimi works with licensed 503B compounding pharmacies that meet strict quality standards. Compounded medications are not FDA-approved but are legal and regulated.
Can I use HSA/FSA for GLP-1?
Yes. GLP-1 medications prescribed by a licensed provider are typically eligible expenses for HSA and FSA accounts. This effectively reduces your cost by your tax rate (20-35% for most people). Confirm with your plan administrator.
How can I make GLP-1 more affordable?
Options include compounded medications (like Trimi), manufacturer savings cards (for brand-name), HSA/FSA accounts, insurance coverage with prior authorization, and patient assistance programs for qualifying individuals.
Affordable GLP-1 Treatment
Trimi offers GLP-1 medication at a fraction of brand-name pricing. No insurance needed.
Get Started TodayMore on Calculators & Tools
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any medication or treatment program.
Sources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).